PegBio Co., Ltd. disclosed on 28 April 2026 that cornerstone investor Yizekangrui Medical (HK) Limited has voluntarily prolonged its lock-up commitment on 9.58 million H shares—equivalent to 3.37% of PegBio’s total issued H shares—until 20 May 2026.

The restriction covers the entire stake acquired at the company’s listing and represents a third consecutive extension. The original six-month lock-up began on the listing date, was first pushed to 31 December 2025, then to 30 April 2026, and is now extended by an additional 20 days.

Management highlighted the extension as evidence of sustained confidence in PegBio’s R&D capabilities and progress toward key clinical milestones. The cornerstone investor will periodically reassess the company’s performance and may contemplate further extensions.

Shareholders and potential investors are advised to exercise caution when trading PegBio securities.